Literature DB >> 9151776

Heparan sulfate proteoglycans of the cardiovascular system. Specific structures emerge but how is synthesis regulated?

R D Rosenberg1, N W Shworak, J Liu, J J Schwartz, L Zhang.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1997        PMID： 9151776      PMCID： PMC508034          DOI： 10.1172/JCI119377

Source DB:  PubMed          Journal:  J Clin Invest        ISSN： 0021-9738            Impact factor:   14.808


× No keyword cloud information.
  83 in total

1.  Molecular cloning and expression of a glycosaminoglycan N-acetylglucosaminyl N-deacetylase/N-sulfotransferase from a heparin-producing cell line.

Authors:  A Orellana; C B Hirschberg; Z Wei; S J Swiedler; M Ishihara
Journal:  J Biol Chem       Date:  1994-01-21       Impact factor: 5.157

2.  Lipoprotein lipase. Molecular model based on the pancreatic lipase x-ray structure: consequences for heparin binding and catalysis.

Authors:  H van Tilbeurgh; A Roussel; J M Lalouel; C Cambillau
Journal:  J Biol Chem       Date:  1994-02-11       Impact factor: 5.157

3.  Smooth muscle cell expression of extracellular matrix genes after arterial injury.

Authors:  S T Nikkari; H T Järveläinen; T N Wight; M Ferguson; A W Clowes
Journal:  Am J Pathol       Date:  1994-06       Impact factor: 4.307

4.  Fine structure of heparan sulfate regulates syndecan-1 function and cell behavior.

Authors:  R D Sanderson; J E Turnbull; J T Gallagher; A D Lander
Journal:  J Biol Chem       Date:  1994-05-06       Impact factor: 5.157

5.  Cellular differences in lipoprotein lipase-mediated uptake of low density lipoproteins.

Authors:  J C Obunike; I J Edwards; S C Rumsey; L K Curtiss; W D Wagner; R J Deckelbaum; I J Goldberg
Journal:  J Biol Chem       Date:  1994-05-06       Impact factor: 5.157

6.  Variable heparan sulfate proteoglycan binding of apolipoprotein E variants may modulate the expression of type III hyperlipoproteinemia.

Authors:  Z S Ji; S Fazio; R W Mahley
Journal:  J Biol Chem       Date:  1994-05-06       Impact factor: 5.157

7.  Activating and inhibitory heparin sequences for FGF-2 (basic FGF). Distinct requirements for FGF-1, FGF-2, and FGF-4.

Authors:  S Guimond; M Maccarana; B B Olwin; U Lindahl; A C Rapraeger
Journal:  J Biol Chem       Date:  1993-11-15       Impact factor: 5.157

8.  Minimal sequence in heparin/heparan sulfate required for binding of basic fibroblast growth factor.

Authors:  M Maccarana; B Casu; U Lindahl
Journal:  J Biol Chem       Date:  1993-11-15       Impact factor: 5.157

9.  cDNA cloning and sequencing of mouse mastocytoma glucosaminyl N-deacetylase/N-sulfotransferase, an enzyme involved in the biosynthesis of heparin.

Authors:  I Eriksson; D Sandbäck; B Ek; U Lindahl; L Kjellén
Journal:  J Biol Chem       Date:  1994-04-08       Impact factor: 5.157

10.  Characterization of ryudocan glycosaminoglycan acceptor sites.

Authors:  N W Shworak; M Shirakawa; R C Mulligan; R D Rosenberg
Journal:  J Biol Chem       Date:  1994-08-19       Impact factor: 5.157
View more
  67 in total

Review 1.  Molecular diversity of heparan sulfate.

Authors:  J D Esko; U Lindahl
Journal:  J Clin Invest       Date:  2001-07       Impact factor: 14.808

2.  Normal levels of anticoagulant heparan sulfate are not essential for normal hemostasis.

Authors:  Sassan HajMohammadi; Keiichi Enjyoji; Marc Princivalle; Patricia Christi; Miroslav Lech; David Beeler; Helen Rayburn; John J Schwartz; Samad Barzegar; Ariane I de Agostini; Mark J Post; Robert D Rosenberg; Nicholas W Shworak
Journal:  J Clin Invest       Date:  2003-04       Impact factor: 14.808

3.  Biosynthesis of heparan sulphate with diverse structures and functions: two alternatively spliced forms of human heparan sulphate 6-O-sulphotransferase-2 having different expression patterns and properties.

Authors:  Hiroko Habuchi; Goichiro Miyake; Ken Nogami; Asato Kuroiwa; Yoichi Matsuda; Marion Kusche-Gullberg; Osami Habuchi; Masayuki Tanaka; Koji Kimata
Journal:  Biochem J       Date:  2003-04-01       Impact factor: 3.857

Review 4.  CS lyases: structure, activity, and applications in analysis and the treatment of diseases.

Authors:  Robert J Linhardt; Fikri Y Avci; Toshihiko Toida; Yeong Shik Kim; Miroslaw Cygler
Journal:  Adv Pharmacol       Date:  2006

Review 5.  A starting place for the road to function.

Authors:  Jeremiah E Silbert; Geetha Sugumaran
Journal:  Glycoconj J       Date:  2002 May-Jun       Impact factor: 2.916

6.  Role of 3-O-sulfated heparan sulfate in virus-induced polykaryocyte formation.

Authors:  Vaibhav Tiwari; Gerdy B ten Dam; Beatrice Y J T Yue; Toin H van Kuppevelt; Deepak Shukla
Journal:  FEBS Lett       Date:  2007-08-24       Impact factor: 4.124

7.  Expanding the role of 3-O sulfated heparan sulfate in herpes simplex virus type-1 entry.

Authors:  Christopher D O'Donnell; Maria Kovacs; Jihan Akhtar; Tibor Valyi-Nagy; Deepak Shukla
Journal:  Virology       Date:  2009-12-11       Impact factor: 3.616

8.  Human follicular fluid heparan sulfate contains abundant 3-O-sulfated chains with anticoagulant activity.

Authors:  Ariane I de Agostini; Ji-Cui Dong; Corinne de Vantéry Arrighi; Marie-Andrée Ramus; Isabelle Dentand-Quadri; Sébastien Thalmann; Patricia Ventura; Victoria Ibecheole; Felicia Monge; Anne-Marie Fischer; Sassan HajMohammadi; Nicholas W Shworak; Lijuan Zhang; Zhenqing Zhang; Robert J Linhardt
Journal:  J Biol Chem       Date:  2008-07-31       Impact factor: 5.157

9.  The Importance of Heparan Sulfate in Herpesvirus Infection.

Authors:  Christopher D O'Donnell; Deepak Shukla
Journal:  Virol Sin       Date:  2008-12-01       Impact factor: 4.327

10.  The endothelial glycocalyx in syndecan-1 deficient mice.

Authors:  Michele D Savery; John X Jiang; Pyong Woo Park; Edward R Damiano
Journal:  Microvasc Res       Date:  2013-02-19       Impact factor: 3.514
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.